A Pilot Study of the Effect of Dietary Fat Type and Amount on Vitamin D3 Absorption
NCT ID: NCT01508845
Last Updated: 2014-07-21
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
61 participants
INTERVENTIONAL
2012-01-31
2013-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Effect of a Meal on Vitamin D Absorption
NCT01268176
The Effect of Fat on Vitamin D Absorption
NCT01519986
Role of Fat Tissue in Vitamin D Metabolism
NCT00033826
Vitamin D3 Supplementation Pilot Study
NCT01546103
25-Hydroxyvitamin D Pharmacokinetic Study
NCT03401541
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
High MUFA/PUFA, 1600 IU vitamin D3
Subjects will receive 3 meals (1 day) with a high MUFA/PUFA ratio (20g/5g), along with 800 IU of vitamin D3 and 800 IU of deuterated vitamin D3
cholecalciferol
800 IU vitamin D3, 1 dose; 800 IU deuterated vitamin D3, 1 dose
High MUFA/PUFA, 50,800 IU vitamin D3
Subjects will receive 3 meals (1 day) with a high MUFA/PUFA ratio (20g/5g), along with 50,000 IU of vitamin D3 and 800 IU of deuterated vitamin D3
cholecalciferol
50,000 IU vitamin D3, 1 dose; 800 IU deuterated vitamin D3, 1 dose
Low MUFA/PUFA, 50,800 IU vitamin D3
Subjects will receive 3 meals (1 day) with a low MUFA/PUFA ratio (5g/20g), along with 50,000 IU of vitamin D3 and 800 IU of deuterated vitamin D3
cholecalciferol
50,000 IU vitamin D3, 1 dose; 800 IU vitamin D3, 1 dose
Fat free meal, 50,800 IU vitamin D3
Subjects will receive 3 fat-free meals (1 day) and 50,000 IU vitamin D3 and 800 IU of deuterated vitamin D3
cholecalciferol
50,000 IU vitamin D3, 1 dose; 800 IU deuterated vitamin D3, 1 dose
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
cholecalciferol
800 IU vitamin D3, 1 dose; 800 IU deuterated vitamin D3, 1 dose
cholecalciferol
50,000 IU vitamin D3, 1 dose; 800 IU deuterated vitamin D3, 1 dose
cholecalciferol
50,000 IU vitamin D3, 1 dose; 800 IU vitamin D3, 1 dose
cholecalciferol
50,000 IU vitamin D3, 1 dose; 800 IU deuterated vitamin D3, 1 dose
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Women must be at least 1 year since last menses
* Subjects must agree not to attend a tanning salon or increase their sun exposure between the screening and final study visits and, for those in the higher vitamin D dose group (50,800 IU), for one month after they have completed the study.
* Subjects must agree not to take more than 400 IU of vitamin D (the amount in most multivitamins) or 1000 mg of calcium per day as their own supplements between the screening and final study visits and, for those in the higher vitamin D dose group (50,800 IU), for one month after completing the study (Note: no supplemental calcium or vitamin D is allowed on the study day.
* Screening serum 25OHD of 25 to 29.5 ng/ml
* Screening BMI 20 to 29.5 kg/m2
* Screening plasma triglyceride concentrations below 150 mg/dL
Exclusion Criteria
* GFR \< 30 ml/min calculated from serum creatinine with use of the Modification of Diet in Renal Disease (MDRD) Study equation \[7\]
* Screening fasting spot urinary calcium:creatinine ratio (Ca:Cr) \> 0.325 (corresponding to a 24-hr urine calcium of 350 mg)
* Screening serum calcium exceeding upper normal limit (reference range 8.3 -10.2 mg/dl)
* Other abnormalities in screening labs, at the discretion of the study physician (PI)
* Sarcoidosis
* Malabsorption, Crohn's disease
* Subjects with disorders of bone and mineral metabolism
* Kidney stones - in the last 3 years
* Evidence of chronic liver disease, including alcoholism
* Cancer treatment in the last year (except basal cell carcinoma) or terminal illness
* Use of lipid lowering medications, plant sterols, fish oil, or flaxseed oil
* Treatment in the last 6 months with estrogen, raloxifene, calcitonin, or testosterone (vaginal estrogen okay)
* Treatment in the last year with teriparatide or denosumab
* Treatment in the last 2 years with bisphosphonates
* Oral corticosteroid therapy for over 3 weeks within the last 6 months
* Anticonvulsant therapy
* High dose thiazide therapy (\>37.5 mg per day)
* Allergy to egg
* Non-English speaking subjects (The food frequency questionnaire to be used in this study has not been validated in other languages. Thus, their diet data would not be able to be included in the analyses. As such, it is inappropriate to expose non-English speaking participants to the study risks, however small, when their data will not contribute to the study results.)
50 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
Tufts University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bess Dawson-Hughes, M.D.
Role: PRINCIPAL_INVESTIGATOR
Tufts Medical Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University
Boston, Massachusetts, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2730
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.